Level of Systolic Blood Pressure Within the Normal Range and Risk of Recurrent Stroke
Bruce Ovbiagele, Hans-Christophe Diener, Salim Yusuf, Renee H Martin, Daniel Cotton, Richard Vinisko, Geoffrey A Donnan, Philip M Bath
JAMA: Journal of the American Medical Association | AMER MEDICAL ASSOC | Published : 2011
All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Ovbiagele reported that he was paid as a consultant by Avanir Pharmaceuticals for 1-time participation in an experts advisory meeting held in June 2011. Dr Diener reported that he receives honoraria for participation in clinical trials, for contribution to advisory boards or oral presentations, and travel expenses and accommodations from Abbott, Allergan, AstraZeneca, Bayer Vital, Bristol-Meyers Squibb, Boehringer Ingelheim, CoAxia, D-Pharm, ev3 Inc, Fresenius, GlaxoSmithKline, Janssen Cilag, Knoll, MSD (formerly Merck Sharpe Dohme), Medtronic, MindFrame, Neurobiological Technologies, Novartis, Novo-Nordisk, Paion, Parke-Davis, Pfizer, sanofi-aventis, Sankyo, Schering-Plough, Servier, Solvay, Thrombogenics, Wyeth, Yamaguchi. Dr Yusuf reported that he receives grants, consulting and speaker fees, and related travel reimbursement from Boehringer Ingelheim and several other companies that manufacture antihypertensive agents and antiplatelet agents. Messrs Cotton and Vinisko reported that they are employees of Boehringer Ingelheim Pharmaceuticals Inc. Dr Bath reported that he receives honoraria for participation in clinical trials or data monitoring committees, contribution to advisory boards, or oral presentations from Boehringer Ingelheim, Lundbeck, Mitsubishi, and M's Science.